Mink Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Barbara Ryan sold 1,500 shares of MiNK Therapeutics, Inc. common stock on June 4, 2026.
NASDAQ
MiNK Therapeutics Director John Bradley Holcomb reports transactions involving the acquisition of common stock and restricted stock units.
NASDAQ
MiNK Therapeutics, Inc. reports that Director Barbara Ryan acquired shares through restricted stock units as compensation.
NASDAQ
MiNK Therapeutics Director Brian Corvese reported transactions involving the acquisition of restricted stock units (RSUs) and common stock.
NASDAQ
Ulf Wiinberg, a Director at MiNK Therapeutics, Inc., reported transactions involving the acquisition of common stock and restricted stock units.
NASDAQ
Director John Bradley Holcomb was granted 4,174 stock options in MiNK Therapeutics, Inc. as part of the company's equity incentive plan.
NASDAQ
A director at MiNK Therapeutics, Barbara Ryan, reported selling 500 shares of common stock in pre-planned transactions.
NASDAQ
MiNK Therapeutics CEO Jennifer Buell filed an amended Form 4 to correct a previous filing, disclosing 10,024 shares withheld for tax purposes.
NASDAQ
MiNK Therapeutics CEO Jennifer Buell received 31,474 shares of common stock as a 2025 performance bonus and 50,000 stock options.
NASDAQ
MiNK Therapeutics director Ulf Wiinberg was granted 5,395 stock options with an exercise price of $11.12, vesting on February 2, 2026.
NASDAQ
MiNK Therapeutics Director Barbara Ryan was granted 5,395 stock options with an exercise price of $11.12, vesting on February 2, 2026.
NASDAQ
MiNK Therapeutics director Brian Corvese was granted 5,395 stock options with an exercise price of $11.12, vesting on February 2, 2026.
NASDAQ
MiNK Therapeutics director Peter Behner was granted 5,395 stock options with an exercise price of $11.12, vesting on February 2, 2026.
NASDAQ
MiNK Therapeutics Director Brian Corvese acquired 1,612 shares of common stock through restricted stock units as compensation.
NASDAQ
MiNK Therapeutics director Peter Behner acquired 1,466 shares of common stock through restricted stock units as compensation.
NASDAQ
MiNK Therapeutics Director Barbara Ryan acquired 1,601 shares of common stock through restricted stock units as part of her board compensation.
NASDAQ
MiNK Therapeutics Director John Bradley Holcomb acquired 1,128 shares of common stock through restricted stock units as compensation.
NASDAQ
MiNK Therapeutics Director Robert Peter Kadlec acquired 1,218 shares of common stock at $11.09 per share, received as restricted stock units in lieu of cash compensation.
NASDAQ
MiNK Therapeutics Director Ulf Wiinberg received 1,263 restricted stock units valued at $11.09 per share as part of his board and committee compensation.
NASDAQ
MiNK Therapeutics CEO Jennifer Buell filed an amended Form 4 to correct previously reported stock transactions related to tax withholdings.
NASDAQ
MiNK Therapeutics Director Peter Behner acquired 3,225 stock options with an exercise price of $15.36, vesting on September 9, 2026.
NASDAQ
MiNK Therapeutics CEO Jennifer Buell received a 2024 performance bonus in common stock and new stock options, as disclosed in a recent SEC Form 4 filing.
NASDAQ
MiNK Therapeutics Director Robert Peter Kadlec was granted 3,225 stock options with an exercise price of $15.36, vesting in one year.
NASDAQ
MiNK Therapeutics Director Brian Corvese was granted 3,225 stock options with an exercise price of $15.36, vesting in one year.
NASDAQ
MiNK Therapeutics director Ulf Wiinberg was granted 3,225 stock options with an exercise price of $15.36, vesting in one year.
NASDAQ
MiNK Therapeutics Director Barbara Ryan was granted 3,225 stock options with an exercise price of $15.36, vesting one year from the grant date.
NASDAQ
MiNK Therapeutics Director Ulf Wiinberg acquired 1,011 shares of common stock through restricted stock units as part of his board compensation.
NASDAQ
MiNK Therapeutics Director Robert Peter Kadlec acquired 975 shares of common stock through restricted stock units as part of his board and committee compensation.
NASDAQ
MiNK Therapeutics Director Barbara Ryan received 1,281 restricted stock units as compensation, vesting one month from the grant date of September 2, 2025.
NASDAQ
MiNK Therapeutics Director Brian Corvese acquired 1,290 shares of common stock through a restricted stock unit grant as part of his board and committee compensation.